modelTeduglutide
Extends from Pharmacolibrary.Drugs.ATC.A.A16AX08.
Information
| name: | Teduglutide | |
| ATC code: | A16AX08 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 103 | L |
| clearance: | 0.15 | L/h/kg |
| other parameters in model implementation | ||
Teduglutide is a recombinant analog of human glucagon-like peptide-2 (GLP-2) used for the treatment of short bowel syndrome (SBS) in adult and pediatric patients who are dependent on parenteral nutrition. It enhances intestinal absorption by promoting mucosal growth, increasing intestinal blood flow, and reducing gastric motility. It is approved and in current use.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects following subcutaneous administration.
References
Marier, JF, et al., & Wallens, J (2010). Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. Journal of clinical pharmacology 50(1) 36–49. DOI:10.1177/0091270009342252 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19773525
Nave, R, et al., & Hartmann, M (2013). Pharmacokinetics of teduglutide in subjects with renal impairment. European journal of clinical pharmacology 69(5) 1149–1155. DOI:10.1007/s00228-012-1455-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23187965
Roepcke, S, et al., & Facius, A (2014). Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome. International journal of clinical pharmacology and therapeutics 52(12) 1045–1058. DOI:10.5414/CP201942 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25066226
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)